Confirming its final draft guidance last month (The Pharma Letter June 1), in final guidance published today (July 25), the UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has recommended German drug major Bayer’s (BAYN: DE) oral anticoagulant Xarelto (rivaroxaban) as an option for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism in adults diagnosed with acute deep vein thrombosis (DVT).
Risk factors for VTE include a history of DVT, recent surgery, immobility, active cancer or cancer treatment, age over 60 years, obesity, hormone replacement therapy or oestrogen containing contraceptive therapy and the presence of co-morbidities such as heart disease. It is estimated that there will be over 46,000 cases of acute DVT in England and Wales during 2012, rising to nearly 50,000 by 2016 due in large part to the aging population.
Treatments for VTE include initiation with injectable anticoagulants such as low-molecular-weight heparin or fondaparinux sodium. Treatment is then overlapped with a vitamin-K antagonist, such as warfarin, until effective anticoagulation with the oral agent is achieved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze